secwatch.observer — SEC 8-K summary
======================================

Issuer:     NGM BIOPHARMACEUTICALS INC (—)
CIK:        0001426332
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001193125-24-046296
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NGM Biopharmaceuticals to be acquired by Column Group affiliates for $1.55/share (80% premium), going private
--------------------------------------------------------------------------------

- Acquisition price $1.55/share in cash, an 80% premium to Dec 29, 2023 closing price before TCG's expression of interest.
- Total equity value ~$135M on fully diluted basis; NGM had ~$166M cash/securities as of Sep 30, 2023, ~$144.2M as of Dec 31.
- Special Committee of independent directors unanimously recommends deal; TCG (26% holder) and rollover stockholders contribute shares instead of cash.
- Tender offer requires majority of unaffiliated shares tendered; no financing condition; expected close Q2 2024; NGM to become private.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426332/000119312524046296/0001193125-24-046296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426332/000119312524046296/d796872d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-046296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer